D J Kerr|W D Alexander - JoVE Visualize

Showing results (171-180 of 219) with videos related to

Pageof 22

Sort By:

Nuclear Medicine Communications|August 1, 1989

Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver diseaseJ A Goldberg, J Fenner, R G Bessent, et al.

Nuclear Medicine Communications|December 1, 1987

Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin IIJ A Goldberg, M S Bradnam, D J Kerr, et al.

Gene Therapy|May 18, 1999

Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954I A McNeish, N K Green, M G Gilligan, et al.

Gene Therapy|May 28, 2004

Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vectorM-J Chen, N K Green, G M Reynolds, et al.

European Journal of Cancer (Oxford, England : 1990)|March 3, 2007

Standard operating procedure for the collection of fresh frozen tissue samplesS R Mager, M H A Oomen, M M Morente, et al.

British Journal of Cancer|July 1, 1991

Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastasesJ A Goldberg, J A Thomson, M S Bradnam, et al.

Cancer Research|December 15, 1987

Phase I and pharmacokinetic study of flavone acetic acidD J Kerr, S B Kaye, J Cassidy, et al.

Cell Death and Differentiation|February 23, 2002

Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cellsA E Milner, D H Palmer, E A Hodgkin, et al.

British Journal of Cancer|March 1, 1990

A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials CommitteeJ Carmichael, B M Cantwell, K A Mannix, et al.

British Journal of Clinical Pharmacology|September 1, 1981

Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazoleL C Low, D C McCruden, W D Alexander, et al.

Pageof 22

Showing results (171-180 of 219) with videos related to

Sort By:

Pageof 22

Nuclear Medicine Communications|August 1, 1989

Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver diseaseJ A Goldberg, J Fenner, R G Bessent, et al.

Nuclear Medicine Communications|December 1, 1987

Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin IIJ A Goldberg, M S Bradnam, D J Kerr, et al.

Gene Therapy|May 18, 1999

Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954I A McNeish, N K Green, M G Gilligan, et al.

Gene Therapy|May 28, 2004

Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vectorM-J Chen, N K Green, G M Reynolds, et al.

European Journal of Cancer (Oxford, England : 1990)|March 3, 2007

Standard operating procedure for the collection of fresh frozen tissue samplesS R Mager, M H A Oomen, M M Morente, et al.

British Journal of Cancer|July 1, 1991

Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastasesJ A Goldberg, J A Thomson, M S Bradnam, et al.

Cancer Research|December 15, 1987

Phase I and pharmacokinetic study of flavone acetic acidD J Kerr, S B Kaye, J Cassidy, et al.

Cell Death and Differentiation|February 23, 2002

Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cellsA E Milner, D H Palmer, E A Hodgkin, et al.

British Journal of Cancer|March 1, 1990

A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials CommitteeJ Carmichael, B M Cantwell, K A Mannix, et al.

British Journal of Clinical Pharmacology|September 1, 1981

Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazoleL C Low, D C McCruden, W D Alexander, et al.

Pageof 22